LLY: 1.5% | Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis; announces $15B share repurchase program, 15% dividend increase

ORCL: -10% | Oracle shares are trading lower following worse-than-expected Q2 financial results.

QURE: 105% | uniQure Reaches Agreement With FDA On Key Elements Of An Accelerated Approval Pathway For AMT-130